The global R&D landscape has experienced a shift in dynamics with the launch of new drugs for a wide range of diseases and a notable acceleration and adaptability of the innovation ecosystem to enhance clinical trial productivity. Biopharma funding levels have rebounded in 2023, with predictive biomarkers, novel trial designs, and decentralized trial methodologies managing complexity and duration.
R&D trends also reveal compelling opportunities in the Asia Pacific market, where emerging biopharma companies are conducting more single-country trials, with novel oncology mechanisms being key drivers.
Get the complete report for detailed insights and strategic opportunities in the biopharma sector here: Global Trends in R&D 2024: Activity, productivity, and enablers
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
.svg){kind=icon}
